Diabetes Accelerates Retinal Neuronal Cell Death In A Mouse Model of Endogenous Hyperhomocysteinemia.
Hyperhomocysteinemia has been implicated in visual dysfunction. We reported recently that mice with endogenous hyperhomocysteinemia, due to mutation of the cystathionine-β-synthase (cbs) gene, demonstrate loss of neurons in the retinal ganglion cell (RGC) layer and other retinal layers as homocysteine levels increase. Some clinical studies implicate hyperhomocysteinemia in the pathogenesis of diabetic retinopathy, which is also characterized by RGC loss. The present study used cbs(+/-) mice to determine whether modest elevation of plasma homocysteine, in the presence of diabetes, accelerates neuronal cell loss. Diabetes (DB) was induced in 3 wk old cbs(+/-) and wildtype mice using streptozotocin; four groups of mice were studied: DB cbs(+/-); non-DB cbs(+/-); DB cbs(+/+); non-DB cbs(+/+). One group of diabetic cbs(+/-) mice was maintained on a high methionine diet (HMD, 0.5% methionine drinking water) to increase plasma homocysteine slightly. Eyes were harvested at 5, 10 and 15 weeks post-onset of diabetes; retinal cryosections were examined by light microscopy and subjected to systematic morphometric analysis. Diabetic cbs(+/-) had significantly fewer RGCs at 5 weeks compared to age-matched, non-diabetic cbs(+/-) and wildtype controls (10.0 ± 0.5 versus 14.9 ± 0.5 and 15.8 ± 0.6 cells/100 µm retina length, respectively). Significant differences in retinas of DB/high homocysteine versus controls were obtained 15 wks post-onset of diabetes including fewer RGCS and decreased thickness of inner nuclear and plexiform layers. Moderate increases in plasma homocysteine coupled with diabetes cause a more dramatic alteration of retinal phenotype than elevated homocysteine or diabetes alone and suggest that diabetes accelerates the retinal neuronal death in hyperhomocysteinemic mice.
Ganapathy
Preethi S
PS
Department of Cellular Biology and Anatomy, Medical College of Georgia, Augusta, Georgia.
Roon
Penny
P
Moister
Tracy K V E
TK
Mysona
Barbara
B
Smith
Sylvia B
SB
Circ Res. 2001 Jun 8;88(11):1203-9
11397788
Eye (Lond). 2008 Aug;22(8):989-93
18064053
J Neural Transm (Vienna). 2002 Dec;109(12):1499-504
12486490
Brain Res Mol Brain Res. 2004 Apr 7;123(1-2):66-75
15046867
Exp Eye Res. 2001 Jul;73(1):45-57
11428862
Invest Ophthalmol Vis Sci. 2004 Sep;45(9):3330-6
15326158
Arterioscler Thromb Vasc Biol. 2008 Sep;28(9):1596-605
18556571
Graefes Arch Clin Exp Ophthalmol. 2005 May;243(5):497-500
15931548
Am J Clin Nutr. 2002 Oct;76(4):897-902
12324306
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Apr;27(2):283-90
12657367
Zhonghua Nei Ke Za Zhi. 2002 Jan;41(1):34-8
11940295
Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1585-9
7878023
Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4460-70
19357353
Arch Ophthalmol. 2005 Aug;123(8):1143-6
16087854
Eur J Ophthalmol. 2008 Mar-Apr;18(2):226-32
18320515
Retina. 2008 May;28(5):741-3
18463519
J Intern Med. 2005 Nov;258(5):450-9
16238681
Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4785-94
17898305
Diabetes. 2006 Sep;55(9):2401-11
16936187
Am J Ophthalmol. 2006 Jan;141(1):201-3
16387004
J Neural Transm (Vienna). 2007;114(5):571-5
17238009
Am J Ophthalmol. 2004 Jan;137(1):84-9
14700648
Am J Clin Nutr. 2000 Feb;71(2):614S-620S
10681269
Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3607-12
19369240
Diabetes. 1997 May;46(5):887-94
9133560
J Neurochem. 2008 Sep;106(5):1977-90
18466320
Cell Death Differ. 2004 Jul;11 Suppl 1:S56-64
15243582
Invest Ophthalmol Vis Sci. 2006 Jul;47(7):3143-50
16799061
J Neural Transm (Vienna). 2007;114(4):445-50
16932990
Trends Neurosci. 2003 Mar;26(3):137-46
12591216
Nutr Metab Cardiovasc Dis. 2008 Jan;18(1):66-73
17027242
Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2210-8
15914643
Diabetes Care. 2008 Jan;31(1):50-6
17898092
J Glaucoma. 2007 Mar;16(2):234-9
17473737
Diab Vasc Dis Res. 2007 Jun;4(2):143-50
17654449
Clin Chim Acta. 2002 Dec;326(1-2):105-12
12417101
Invest Ophthalmol Vis Sci. 2008 Sep;49(9):4154-61
18469181